hero media helmsley

Our Grants

GRANT DATE AMOUNT PROGRAM
American Gastroenterological Association Institute
Amplifying Learning from the Cedars-Sinai Advanced Dietary IBD Education and Training (DIET) Program: Beyond Malnutrition
05.09.2023 $138,957.00 Crohn's Disease, Disease Management
Cornell University
Sponsorship for the 25th anniversary Adherent Invasive E. coli (AIEC) meeting
04.12.2023 $15,000.00 Crohn's Disease, Diagnostics
The Imperial College of Science, Technology and Medicine
Unraveling the immunopathology of perianal fistulizing Crohn's disease
02.08.2023 $3,111,800.00 Crohn's Disease, Disease Biology
Johns Hopkins University
Engineered Cytokine/Antibody Fusion Protein to Treat Crohn's Disease
02.08.2023 $1,500,000.00 Crohn's Disease, Therapeutics
The Regents of the University of California, San Diego
The Druggable GPCRome in Crohn's Disease
02.08.2023 $3,494,185.00 Crohn's Disease, Therapeutics
Cornell University for the Joan & Sanford I. Weill Medical College of Cornell University
Targeting the mycobiome in patients with Crohn's Disease
02.08.2023 $1,929,856.00 Crohn's Disease, Therapeutics
Regents of The University of Michigan
Evaluation of a Gut-Specific Antifibrotic Therapeutic in Pre-clinical Models of Crohn's Disease
01.25.2023 $558,806.00 Crohn's Disease, Therapeutics
Washington University
Cellular biomarkers for pediatric Crohn's disease
01.25.2023 $1,015,114.00 Crohn's Disease, Diagnostics
London North West University Healthcare NHS Trust
Perianal Crohn's Disease Consortium
01.25.2023 $69,442.00 Crohn's Disease, Diagnostics
The Broad Institute, Inc.
Uncovering Crohn's genetic risk in African-American and Hispanic/Latino populations
01.25.2023 $3,057,442.00 Crohn's Disease, Disease Biology
Children's Hospital Medical Center
Role of PPAR-alpha in promoting brush border maturity of intestinal enterocytes
01.25.2023 $838,931.00 Crohn's Disease, Disease Biology
Chancellor Masters & Scholars Of The University Of Oxford
Interrogating the mechanism of hypersensitivity to antibody-based drugs for development of a novel anti-TNF biologic for Crohn's disease
12.20.2022 $474,279.00 Crohn's Disease, Therapeutics
Clalit Health Services
Israeli IBD Research Nucleus (IIRN) Consortium Management
11.08.2022 $422,087.00 Crohn's Disease, Other
Clalit Health Services
Israeli IBD Research Nucleus (IIRN) Consortium: Biomarker-Based Multidisciplinary Team Approach to Improve Early Crohn's Disease Outcomes
11.08.2022 $1,360,291.00 Crohn's Disease, Other
The Sheba Fund for Health Services and Research (R.A.)
Israel IBD Research Nucleus (IIRN) Consortium: Capsule & Omics for pRedicting Exacerbation of Crohn's disease (CORE-CD)
11.08.2022 $2,447,647.00 Crohn's Disease, Other
Rambam Health Corporation
Israeli IBD Research Nucleus (IIRN) Consortium: Microbial and Dietary Effects on Immune Composition and Function in Patients with Crohn's disease: Spatial Microbial Cellular Interactions & Effects on Immunogenicity
11.08.2022 $2,885,540.00 Crohn's Disease, Other
Shaare Zedek Medical Center
Israeli IBD Research Nucleus (IIRN) Consortium: Combining Multi-Tier Administrative Data for Facilitating Disease Free Management
11.08.2022 $3,066,299.00 Crohn's Disease, Other
Ben-Gurion University of the Negev
Israeli IBD Research Nucleus (IIRN) Consortium: COBMINDEX goes forward- A Smartphone application for added psychological wellbeing in Crohn's disease.
11.08.2022 $2,770,874.00 Crohn's Disease, Other
The Weizmann Institute of Science
Decoding the clinical impact of host and microbial intestinal proteomic landscape in Crohn's disease
11.08.2022 $1,662,735.00 Crohn's Disease, Diagnostics
The Chancellor, Masters and Scholars of the University of Cambridge
Epigenetic regulation of intestinal epithelial MHC class 1 signalling - a novel mechanism in the pathogenesis of Crohn's Disease
11.08.2022 $2,142,788.00 Crohn's Disease, Disease Biology
You can filter rows:
1 - 20 of 224 <   > Last